News & Views
Acquisition Brings Parkinson’s Treatment to Lundbeck
Mar 28 2018
The signing of a definitive agreement, that will see international pharmaceutical business H. Lundbeck A/S acquire Prexton Therapeutics BV, will bring a potential candidate for treatment of Parkinson’s to the Danish company. Under terms of the agreement, Lundbeck will pay €100 million upfront plus €805 million in development and sales milestones.
It will obtain global rights for foliglurax, which is currently in clinical phase II testing for the symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia (uncontrolled movements) including Levodopa Induced Dyskinesia (LID). First data from the ongoing clinical phase II program is expected to be available in mid-2019.
"We are very excited to be working with Lundbeck, a company with a strong history and focus on diseases of the central nervous system," said François Conquet, Ph.D, founder and chief executive Officer, of Netherlands-based Prexton. "Lundbeck shares our vision for the development of foliglurax to help patients living with Parkinson’s disease.”
Digital Edition
Lab Asia 31.4 August 2024
August 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers Labo...
View all digital editions
Events
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 18 2024 Lausanne, Switzerland
Sep 19 2024 Shanghai, China